3D Neuroscience Market Report 2026

The three-dimensional (3D) neuroscience market size has grown rapidly in recent years. It will grow from $1.49 billion in 2025 to $1.71 billion in 2026 at a compound annual growth rate (CAGR) of 14.8%. The growth in the historic period can be attributed to growing adoption of three-dimensional (3D) brain modeling techniques, increasing demand for advanced neurological research tools, rising use in drug discovery and neuropharmacology, expansion of imaging and visualization technologies, and growing focus on understanding complex neural networks.

The three-dimensional (3D) neuroscience market size is expected to see rapid growth in the next few years. It will grow to $2.95 billion in 2030 at a compound annual growth rate (CAGR) of 14.5%. The growth in the forecast period can be attributed to increasing integration of three-dimensional (3D) models with artificial intelligence (AI) analytics, rising investment in personalized neuroscience research, growing adoption in disease modeling and therapeutic development, expansion of high-resolution imaging and data acquisition platforms, and a rise in demand for predictive and translational neuroscience studies. Major trends in the forecast period include technology-driven innovations in three-dimensional (3D) neural tissue modeling, advancements in artificial intelligence (AI)-enabled data analysis, developments in organoid and lab-grown neural systems, rising research and development in imaging and simulation platforms, and innovation in integrated neuroscience modeling and visualization tools.

The increasing prevalence of neurological disorders is expected to propel the growth of the 3D neuroscience market going forward. Neurological disorders are medical conditions that affect the brain, spinal cord, and nerves, disrupting normal nervous system function and leading to impairments in movement, cognition, sensation, behavior, or overall bodily control. The increasing prevalence of neurological disorders is due to unhealthy lifestyle habits, including poor diet, physical inactivity, smoking, excessive alcohol consumption, and chronic stress. 3D neuroscience enhances understanding of the brain’s structure and function, enabling more precise diagnosis and personalized treatment for neurological patients. For instance, in April 2024, according to the National Institutes of Health (NIH), a US-based government agency, an estimated 6.9 million Americans aged 65 and older are currently living with Alzheimer’s dementia, and this figure is projected to nearly double to 13.8 million by 2060. Therefore, the increasing prevalence of neurological disorders drives the 3D neuroscience market.

Key players operating in the 3D neuroscience market are focusing on developing advanced 3D human brain tissue platforms, such as multicellular integrated brain models, to enhance disease modeling, accelerate drug testing, and provide more physiologically relevant results. Multicellular integrated brain models refer to laboratory-cultured three-dimensional constructs derived from induced pluripotent stem cells that incorporate multiple major brain cell types, enabling detailed study of cellular interactions, pathology, and drug responses. For instance, in November 2025, Massachusetts Institute of Technology (MIT), a US-based research institution, launched Multicellular Integrated Brains (miBrains), a customizable 3D human brain tissue system. The platform integrates six major brain cell types, supports genetic engineering for personalized disease studies, and can be scaled to support large-scale research projects, improving the supply and usability of complex in vitro models for neuroscience research.

In December 2023, Mentice AB, a Sweden-based provider of medical simulation and image-guided interventional therapy solutions, acquired Biomodex for an undisclosed amount. Through this acquisition, Mentice aims to enhance its 3D anatomical printing and simulation capabilities by incorporating patient-specific, high-fidelity 3D models that support advanced clinical planning, physician training, and neurovascular procedural rehearsal. Biomodex is a UK-based medical technology company specializing in biorealistic 3D-printed anatomical models and patient-specific simulation systems.

Major companies operating in the 3D neuroscience market are Siemens Healthineers AG, Merck KGaA, Koninklijke Philips N.V., GE Healthcare Technologies Inc., Corning Incorporated, Bruker Corporation, STEMCELL Technologies Inc., Greiner Bio-One International GmbH, American Type Culture Collection, Cellink AB, Aspect Biosystems Ltd., InSphero AG, Axion BioSystems Inc., Emulate Inc., Mimetas B.V., NeuroNexus Technologies Inc., Tessara Therapeutics Inc., TheWell Bioscience Inc., Kirkstall Ltd., Pelobiotech GmbH, 3D Biotek LLC, Mightex Systems Inc., Advanced BioMatrix Inc.

North America was the largest region in the three dimensional (3D) neuroscience market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the 3D neuroscience market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the 3D neuroscience market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

Tariffs are impacting the 3D neuroscience market by increasing costs of imported imaging instruments, sensors, high-performance computing hardware, optical components, and specialized laboratory equipment. research institutions in north america and europe are most affected due to reliance on imported advanced tools, while asia-pacific faces higher costs for equipment acquisition and collaboration projects. these tariffs are raising research infrastructure costs and extending procurement timelines. however, they are also encouraging domestic instrument development, regional manufacturing of research tools, and localized software innovation in neuroscience analytics.

3D neuroscience involves the use of three-dimensional (3D) technologies to visualize, analyze, and model the structure and function of the nervous system with high spatial resolution. Its primary objective is to facilitate precise mapping of brain circuits, neural connectivity, and cellular interactions for advanced research and diagnostic applications. It also enhances understanding of neurological disorders, brain development, and neural network behavior through immersive, data-rich visualization.

The primary components of 3D neuroscience include instruments and consumables, along with software and services. Instruments and consumables refer to advanced imaging, analysis, and visualization tools used to observe and analyze three-dimensional brain structures and neural networks with high spatial precision. The technologies include brain imaging, neuro-microscopy, electrophysiology, neurophotonic analysis, and others. The various study scales include macro-scale, meso-scale, micro-scale, and nanoscale or synaptic levels. Applications include disease modeling and drug discovery, brain mapping and connectomics, developmental neuroscience, diagnostics, and surgical planning, with major end users including hospitals, diagnostic laboratories, research institutions, academic institutes, and others.

The 3D neuroscience market consists of revenues earned by entities by providing services such as three-dimensional (3D) brain imaging platforms, neural reconstruction software, volumetric data analysis tools, virtual brain modeling systems, and advanced microscopy integration. The market value includes the value of related goods sold by the service provider or included within the service offering. The 3D neuroscience includes sales of high-resolution imaging hardware, optical microscopy systems, three-dimensional (3D) imaging scanners, and neural data visualization workstations. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.